



## Synthesis and acetylcholinesterase inhibitory activity of polyhydroxylated sulfated steroids: Structure/activity studies



Victoria Richmond<sup>a</sup>, Ana P. Murray<sup>b</sup>, Marta S. Maier<sup>a,\*</sup>

<sup>a</sup> UMYMFOR (CONICET-UBA) and Departamento de Química Orgánica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Ciudad Universitaria, Pabellón 2, 1428 Buenos Aires, Argentina

<sup>b</sup> INQUISUR, Departamento de Química, Universidad Nacional del Sur, Avda. Alem 1253, 8000 Bahía Blanca, Buenos Aires, Argentina

### ARTICLE INFO

#### Article history:

Received 10 June 2013

Received in revised form 25 July 2013

Accepted 6 August 2013

Available online 20 August 2013

#### Keywords:

Sulfated steroids

Synthesis

Acetylcholinesterase activity

### ABSTRACT

Disulfated and trisulfated steroids have been synthesized from cholesterol and their acetylcholinesterase inhibitory activity has been evaluated. In our studies we have found that the activity was not only dependent on the location of the sulfate groups but on their configurations. 2 $\beta$ ,3 $\alpha$ ,6 $\alpha$ -trihydroxy-5 $\alpha$ -cholestan-6-one trisulfate (**18**) was the most active steroid with an IC<sub>50</sub> value of 15.48  $\mu$ M comparable to that of 2 $\beta$ ,3 $\alpha$ -dihydroxy-5 $\alpha$ -cholestan-6-one disulfate (**1**). Both compounds were found to be less active than the reference compound eserine. The butyrylcholinesterase activity of **1** and **18** was one magnitude lower than that against acetylcholinesterase revealing a selective inhibitor profile.

© 2013 Elsevier Inc. All rights reserved.

### 1. Introduction

Alzheimer's disease (AD) is an age-related neurodegenerative process characterized by a progressive memory loss, decline in language skills and other cognitive impairments [1]. According to the cholinergic hypothesis, the selective and irreversible deficiency of cholinergic functions leads to memory impairment in AD [2]. Acetylcholine serves as a neurotransmitter in the central and peripheral nervous system. Acetylcholinesterase (AChE), located either in peripheral (muscles) and/or central nervous (cholinergic) system, stops the function of acetylcholine by its hydrolytic destruction in the cholinergic synapses [3]. Another cholinesterase, namely butyrylcholinesterase (BChE), is involved in the metabolic degradation of acetylcholine and differs from AChE in tissue distribution and sensitivity to substrates and inhibitors. The relative proportions of AChE to BChE depend on the brain regions and the stage of disease progression in AD patients [4]. BChE activity increases as AD progresses, which suggests that BChE may also play an important role in cholinergic dysfunction, particularly at the latter stages of AD. For this reason, the administration of inhibitors with different AChE/BChE selectivity should be very useful as AD progresses [5].

Enhancement of acetylcholine level in the brain is considered one of the most promising approaches for treating AD [6]. Retaining the neurotransmitters especially at the synaptic terminals via the inhibition of the hydrolytic enzymes, i.e., the cholinesterases,

in order to compensate the deficiency of the cholinergic neurotransmitters would lead to the improved cognitive activities of the patient and related conditions such as Lewy Body dementia, subcortical vascular dementia and Parkinson's disease [7,8].

The enhancement of the inhibitory activity against AChE by sulfation of calenduladiol, a pentacyclic triterpene isolated from *Chuquiraga erinacea*, (IC<sub>50</sub> from 94 to 0.190 mM) [9] prompted us to test the acetylcholinesterase inhibitory activity of two sulfated compounds, disodium 2 $\beta$ ,3 $\alpha$ -dihydroxy-5 $\alpha$ -cholestan-6-one disulfate (**1**) and disodium 2 $\beta$ ,3 $\alpha$ -dihydroxy-5 $\alpha$ -cholestane disulfate (**2**), and compare it to their corresponding diols (**3** and **4**) (Fig. 1) [10,11]. The results were indicative of the role of the sulfate groups in the AChE inhibitory activity of **1** and **2** and showed that the presence of a carbonyl group at C-6 in **1** increases the activity [11]. In this report, we synthesized disulfated and trisulfated steroids with sulfate groups at C-2, C-3 and C-6 ( $\alpha/\beta$  configurations) on ring A and B and determined their acetylcholinesterase inhibitory activity. Interestingly, we found that the activity of the sulfated steroids is not only dependent on the location of the sulfate groups but on their configurations. Our results provide new evidence for the relationship between chemical structure and acetylcholinesterase inhibitory activity.

### 2. Experimental

#### 2.1. General methods

Melting points (m.p.) were determined on a Fisher Johns apparatus and are uncorrected. <sup>1</sup>H NMR, <sup>13</sup>C NMR, HSQC-DEPT, HMBC, COSY and NOESY spectra were recorded on a Bruker AM

\* Corresponding author. Tel./fax: +54 11 4576 3385.

E-mail address: [maier@qo.fcen.uba.ar](mailto:maier@qo.fcen.uba.ar) (M.S. Maier).

500 spectrometer. Chemical shifts ( $\delta$ ) are given in ppm downfield from TMS as the internal standard. 2D NMR spectra were obtained using standard Bruker software. High resolution mass spectra were determined on a Bruker micrOTOF-Q II mass spectrometer with ESI as ionization source. IR spectra were acquired on a FT-IR Nicolet Magna 550 spectrometer and on a Perkin Elmer Spectrum 400 with an ATR accessory. UV spectra were recorded on a JASCO V-630BIO spectrophotometer. Elemental analysis was performed on an EAI Exeter Analytical, Inc. CE-440 apparatus. Microwave assisted reactions were carried out in a CEM Discover reactor. Analytical thin layer chromatography (TLC) was performed on pre-coated silica plates (Merck F<sub>254</sub>, 0.2 mm thickness); TLC of sulfated steroids was performed on silica gel F<sub>254</sub> (*n*-BuOH/AcOH/H<sub>2</sub>O (12:3:5)) and detected by spraying with sulfuric acid (10% H<sub>2</sub>O). Flash column chromatography was performed with silica gel Merck 60 G (90% < 45  $\mu$ m). Solid phase extraction tubes of silica gel (55  $\mu$ m) were purchased from Phenomenex. Preparative HPLC was carried out on an SP liquid chromatograph equipped with a Spectra Series P100 solvent delivery system, a Rheodyne manual injector and a refractive index detector using a Phenomenex AQUA 5  $\mu$  C<sub>18</sub> 125A column. All chemicals and solvents were analytical grade and solvents were purified by general methods before being used.

The commercially available trimethylamine-sulfur trioxide complex was purchased from Aldrich. 2 $\beta$ ,3 $\alpha$ -Dihydroxy-5 $\alpha$ -cholestan-6-one (**3**) was used as starting material for the synthesis of compounds **10–14** and 5 $\alpha$ -cholest-2-en-6-one (**5**), to obtain the rest of the compounds (i.e. **6–9** and **15–18**). Compounds **3** and **5** were obtained following the procedure described in our previous work [11]. Acetylcholinesterase (electric eel), 5,5'-dithiobis(2-nitrobenzoic acid) (DTNB), acetylthiocholine iodide (ATCI), butyrylthiocholine iodide (BTCI) and eserine were purchased from Sigma. Butyrylcholinesterase (horse serum) was purchased from MP Biomedicals.

## 2.2. 2 $\beta$ ,3 $\beta$ -Dihydroxy-5 $\alpha$ -cholestan-6-one (**6**)

Asymmetric dihydroxylation reactions were performed on 5 $\alpha$ -cholest-2-en-6-one (**5**) using the experimental conditions reported by Sharpless [12]. A solution of **5** (50 mg, 0.13 mmol) in *tert*-butyl alcohol (2 ml) was added to a solution of AD-mix- $\alpha$  (181.7 mg) in water (2 ml). The mixture was stirred for few minutes at room temperature until two clear phases were observed. Methanesulphonamide (12.5 mg, 0.13 mmol) was added and the mixture was stirred at room temperature for two weeks. Then, a saturated sodium bisulphite solution (1.7 ml) was added to the cold reaction mixture and the suspension was stirred for 30 min at room temperature. After extraction with EtOAc (3  $\times$  5 ml), the combined organic extracts were washed successively with 2 N KOH solution (3  $\times$  5 ml) and water, dried over anhydrous MgSO<sub>4</sub> and evaporated to dryness. The reaction product was submitted to column chromatography on silica gel (0.063–0.200 mm), eluted with cyclohexane/EtOAc (60:40 v/v) and evaporated under reduced pressure to afford pure 2 $\beta$ ,3 $\beta$ -dihydroxy-5 $\alpha$ -cholestan-6-one (**6**)




Fig. 1. Chemical structures of acetylcholinesterase inhibitors (**1**, **2**) and inactive diols (**3**, **4**).

(35.4 mg, 65%), m.p. 203–204 °C (acetone–H<sub>2</sub>O) and 2 $\alpha$ ,3 $\alpha$ -dihydroxy-5 $\alpha$ -cholestan-6-one (**8**) (19 mg, 35%). <sup>1</sup>H NMR  $\delta$  (CDCl<sub>3</sub>): 0.66 (s, 3H, H-18), 0.86 (d, *J* = 6.6 Hz, 6H, H-26, H-27), 0.91 (d, *J* = 6.6 Hz, 3H, Me-21), 0.98 (s, 3H, H-19), 3.63 (dt, *J* = 11.7 Hz, 4.2 Hz, H-3 $\alpha$ ), 4.03 (m, 1H, H-2 $\alpha$ ). <sup>13</sup>C NMR  $\delta$  (CDCl<sub>3</sub>): 42.6 (C-1), 69.3 (C-2), 72.0 (C-3), 24.4 (C-4), 57.3 (C-5), 210.8 (C-6), 46.6 (C-7), 37.4 (C-8), 54.9 (C-9), 40.7 (C-10), 21.7 (C-11), 39.7 (C-12), 43.2 (C-13), 56.8 (C-14), 24.1 (C-15), 28.2 (C-16), 56.3 (C-17), 12.2 (C-18), 15.4 (C-19), 35.8 (C-20), 18.8 (C-21), 36.2 (C-22), 24.0 (C-23), 39.6 (C-24), 28.2 (C-25), 22.7 (C-26, C-27). Anal. calcd for C<sub>27</sub>H<sub>46</sub>O<sub>3</sub>·½H<sub>2</sub>O, C 75.82, H 11.08, O 13.10. Found, C 75.46, H 11.29. HREIMS (ESI+), calculated for C<sub>27</sub>H<sub>46</sub>NaO<sub>3</sub> [M + Na<sup>+</sup>]: 441.3339, found *m/z* = 441.3322. FT-IR (NaBr, film, cm<sup>-1</sup>) 3525, 3464 ( $\nu$  O–H), 1696 ( $\nu$  C=O), 1454 ( $\delta_{as}$  CH<sub>3</sub>), 1363 ( $\delta_s$  CH<sub>3</sub>).

## 2.3. Disodium 2 $\beta$ ,3 $\beta$ -dihydroxy-5 $\alpha$ -cholestan-6-one disulfate (**7**)

Trimethylamine-sulfur trioxide complex (25.7 mg, 0.19 mmol) was added to a solution of 2 $\beta$ ,3 $\beta$ -dihydroxy-5 $\alpha$ -cholestan-6-one (**6**) (10 mg, 0.024 mmol) in DMF (1 ml). The reaction mixture was irradiated and stirred at 150 °C for 7 min in a sealed tube in a microwave reactor and then quenched with water (1 ml). After evaporation to dryness the residue was eluted through Amberlite CG-120 (sodium form) with methanol, evaporated under reduced pressure and purified by solid phase extraction over silica gel (55  $\mu$ m). Fractions eluted with CH<sub>2</sub>Cl<sub>2</sub>/MeOH (85:15) afforded pure disodium 2 $\beta$ ,3 $\beta$ -dihydroxy-5 $\alpha$ -cholestan-6-one disulfate (**7**) (11.8 mg, 79.4%), m.p. 210–215 °C (decomp). <sup>1</sup>H NMR  $\delta$  (CDOD<sub>3</sub>): 0.71 (s, 3H, H-18), 0.88 (d, *J* = 6.6 Hz, 6H, H-26, H-27), 0.95 (d, *J* = 6.4 Hz, 3H, Me-21), 1.00 (s, 3H, H-19), 4.31 (dt, *J* = 12.1 Hz, 3.7 Hz 1-H, H-3 $\alpha$ ), 4.84 (m, 1H, H-2 $\alpha$ ). <sup>13</sup>C NMR  $\delta$  (CDOD<sub>3</sub>): 41.7 (C-1), 76.5 (C-2), 78.3 (C-3), 23.6 (C-4), 58.3 (C-5), 213.2 (C-6), 47.1 (C-7), 38.8 (C-8), 55.5 (C-9), 42.0 (C-10), 25.0 (C-11), 40.9 (C-12), 44.2 (C-13), 57.7 (C-14), 24.9 (C-15), 29.2 (C-16), 57.5 (C-17), 12.4 (C-18), 15.6 (C-19), 37.1 (C-20), 19.1 (C-21), 37.3 (C-22), 22.7 (C-23), 40.7 (C-24), 29.2 (C-25), 22.9 (C-26), 23.2 (C-27). HREIMS (ESI–), calculated for C<sub>27</sub>H<sub>44</sub>NaO<sub>5</sub>S<sub>2</sub> [M–Na]<sup>–</sup>: 599.2330, found *m/z* = 599.2355. ATR FT-IR (ZnSe, cm<sup>-1</sup>) 1699 ( $\nu$  C=O), 1463 ( $\delta_{as}$  CH<sub>3</sub>), 1376 ( $\delta_s$  CH<sub>3</sub>), 1220 ( $\delta_s$  S=O).

## 2.4. 2 $\alpha$ ,3 $\alpha$ -Dihydroxy-5 $\alpha$ -cholestan-6-one (**8**)

Asymmetric dihydroxylation reactions were performed on cholest-2-en-6-one (**5**) using the experimental conditions reported by Sharpless [12]. A solution of **5** (200 mg, 0.52 mmol) in *tert*-butyl alcohol (5.8 ml) was added to a solution of AD-mix- $\beta$  (732 mg) in water (5.8 ml). The mixture was stirred for few minutes at room temperature until two clear phases were observed. Methanesulphonamide (49.3 mg, 0.51 mmol) was added and the mixture was stirred at room temperature for two weeks. Then, a saturated sodium bisulphite solution (6.6 ml) was added to the cold reaction mixture and the suspension was stirred for 30 min at room temperature. After extraction with EtOAc (3  $\times$  15 ml), the combined organic extracts were washed successively with 2 N KOH solution (3  $\times$  15 ml) and water, dried over anhydrous MgSO<sub>4</sub> and evaporated to dryness. The reaction product was submitted to column chromatography on silica gel (0.063–0.200 mm), eluted with cyclohexane/EtOAc (60:40 v/v) and evaporated under reduced pressure to afford pure 2 $\alpha$ ,3 $\alpha$ -dihydroxy-5 $\alpha$ -cholestan-6-one (**8**) (123.4 mg, 65%), m.p. 199–200 °C (acetone–H<sub>2</sub>O) and 2 $\beta$ ,3 $\beta$ -dihydroxy-5 $\alpha$ -cholestan-6-one (**6**) (67.3 mg, 35%), together with 12.4 mg of **5**. <sup>1</sup>H NMR  $\delta$  (CDCl<sub>3</sub>): 0.66 (s, 3H, H-18), 0.74 (s, 3H, H-19), 0.85 (d, *J* = 6.7 Hz, 3H, H-26), 0.86 (d, *J* = 6.8 Hz, 3H, H-27), 0.91 (d, *J* = 6.5 Hz, 3H, Me-21), 3.75 (ddd, *J* = 11.8 Hz, 4.7 Hz, 3.2 Hz, H-2 $\beta$ ), 4.03 (m, 1H, H-3 $\beta$ ). <sup>13</sup>C NMR  $\delta$  (CD<sub>3</sub>OD): 40.3 (C-1), 68.4 (C-2), 68.5 (C-3), 26.4 (C-4), 50.9 (C-5), 212.5 (C-6), 46.9 (C-7), 37.8 (C-8), 53.9 (C-9), 42.7 (C-10), 21.3 (C-11), 39.5 (C-12), 43.1

(C-13), 56.8 (C-14), 24.1 (C-15), 28.2 (C-16), 56.2 (C-17), 12.2 (C-18), 13.7 (C-19), 35.8 (C-20), 18.8 (C-21), 36.2 (C-22), 24.0 (C-23), 39.6 (C-24), 28.1 (C-25), 22.7 (C-26), 23.0 (C-27). Anal. calcd for  $C_{27}H_{46}O_3 \cdot \frac{1}{2}H_2O$ , C 75.83, H 11.07, O 13.10. Found, C 75.86, H 11.14. HREIMS (ESI+), calculated for  $C_{27}H_{46}NaO_3$  [ $M + Na^+$ ]: 441.3339, found  $m/z = 441.3323$ . FT-IR (NaBr, film,  $cm^{-1}$ ) 3348, 3523 ( $\nu$  O–H), 1710 ( $\nu$  C=O), 1463 ( $\delta_{as}$  CH<sub>3</sub>), 1380 ( $\delta_s$  CH<sub>3</sub>).

#### 2.5. Disodium 2 $\alpha$ ,3 $\alpha$ -dihydroxy-5 $\alpha$ -cholestan-6-one disulfate (**9**)

Trimethylamine-sulfur trioxide complex (25.7 mg, 0.19 mmol) was added to a solution of 2 $\alpha$ ,3 $\alpha$ -dihydroxy-5 $\alpha$ -cholestan-6-one (**8**) (10 mg, 0.024 mmol) in DMF (1 ml). The reaction mixture was irradiated and stirred at 150 °C for 7 min in a sealed tube in a microwave reactor and then quenched with water (1 ml). After evaporation to dryness the residue was eluted through Amberlite CG-120 (sodium form) with methanol, evaporated under reduced pressure and purified by solid phase extraction over silica gel (55  $\mu$ m). Fractions eluted with  $CH_2Cl_2/MeOH$  (85:15) afforded pure disodium 2 $\alpha$ ,3 $\alpha$ -dihydroxy-5 $\alpha$ -cholestan-6-one disulfate (**9**) (11.6 mg, 77.6%), m.p. 195–208 °C (decomp).  $^1H$  NMR  $\delta$  (CDOD<sub>3</sub>): 0.69 (s, 3H, H-18), 0.82 (s, 3H, H-19), 0.86 (d,  $J = 6.6$  Hz, 3H, H-26), 0.87 (d,  $J = 6.6$  Hz, 3H, H-27), 0.93 (d,  $J = 6.5$  Hz, 3H, Me-21), 4.44 (ddd,  $J = 12.3, 4.7, 3$  Hz, 1H, H-2 $\beta$ ), 4.86 (m, 1-H, H-3 $\beta$ ).  $^{13}C$  NMR  $\delta$  (CDOD<sub>3</sub>): 39.6 (C-1), 75.4 (C-2), 76.4 (C-3), 25.9 (C-4), 52.3 (C-5), 214.3 (C-6), 47.4 (C-7), 39.2 (C-8), 55.0 (C-9), 43.7 (C-10), 24.9 (C-11), 40.8 (C-12), 44.2 (C-13), 57.8 (C-14), 25.0 (C-15), 29.2 (C-16), 57.4 (C-17), 12.4 (C-18), 14.0 (C-19), 37.0 (C-20), 19.1 (C-21), 37.3 (C-22), 22.4 (C-23), 40.7 (C-24), 29.2 (C-25), 22.9 (C-26), 23.2 (C-27). HREIMS (ESI–), calculated for  $C_{27}H_{44}NaO_9S_2$  [ $M - Na$ ]<sup>–</sup>: 599.2330, found  $m/z = 599.2349$ . ATR FT-IR (ZnSe,  $cm^{-1}$ ) 1702 ( $\nu$  C=O), 1463 ( $\delta_{as}$  CH<sub>3</sub>), 1379 ( $\delta_s$  CH<sub>3</sub>), 1218 ( $\delta_s$  S=O).

#### 2.6. 2 $\beta$ ,3 $\alpha$ ,6 $\beta$ -Trihydroxy-5 $\alpha$ -cholestane (**10**)

Three portions of 0.5 ml of a solution of 4.5 mg/ml of sodium borohydride in methanol were added to a solution of 19.5 mg (0.046 mmol) of 2 $\beta$ ,3 $\alpha$ -dihydroxy-5 $\alpha$ -cholestan-6-one (**3**) in 1.25 ml of methanol and the mixture was stirred at room temperature overnight. After acidification with 0.5 M HCl solution, methanol was added and the mixture was evaporated to eliminate the B(OMe)<sub>3</sub>. Then, water was added and the steroid was extracted with EtOAc (3  $\times$  10 ml). The combined organic extracts were washed with water, dried over anhydrous MgSO<sub>4</sub>, filtered and evaporated to dryness. The crude triol **10** was purified by solid phase extraction over silica gel (55  $\mu$ m). Fractions eluted with cyclohexane/EtOAc (70:30) afforded pure 2 $\beta$ ,3 $\alpha$ ,6 $\beta$ -trihydroxy-5 $\alpha$ -cholestane (**10**) (16.8 mg, 87%), m.p. >250 °C (acetone–H<sub>2</sub>O).  $^1H$  NMR  $\delta$  (CD<sub>3</sub>OD): 0.72 (s, 3H, H-18), 0.88 (d,  $J = 6.6$  Hz, 6H, H-26, H-27), 0.94 (d,  $J = 6.5$  Hz, 3H, Me-21), 1.18 (s, 3H, H-19), 1.62 (m, 1H, H-5 $\alpha$ ), 3.79 (m, 1H, H-2 $\alpha$ ), 3.71 (m, H-6 $\alpha$ ), 3.86 (m, 1H, H-3 $\beta$ ).  $^{13}C$  NMR  $\delta$  (CD<sub>3</sub>OD): 42.6 (C-1), 72.2 (C-2), 71.4 (C-3), 30.1 (C-4), 43.1 (C-5), 72.9 (C-6), 40.7 (C-7), 31.3 (C-8), 57.7 (C-9), 37.1 (C-10), 24.9 (C-11), 40.4 (C-12), 43.9 (C-13), 56.7 (C-14)\*, 25.3 (C-15), 29.3 (C-16), 57.7 (C-17)\*, 12.6 (C-18), 18.3 (C-19), 37.0 (C-20), 19.2 (C-21), 37.4 (C-22), 21.8 (C-23), 40.7 (C-24), 29.1 (C-25), 22.9 (C-26), 23.2 (C-27). Anal. calcd for  $C_{27}H_{48}O_3 \cdot \frac{3}{4}H_2O$ , C 74.69, H 11.49, O 13.82. Found, C 74.26, H 11.58. HREIMS (ESI+), calculated for  $C_{27}H_{48}NaO_3$  [ $M + Na^+$ ]: 443.3496, found  $m/z = 443.3479$ . ATR FT-IR (ZnSe,  $cm^{-1}$ ) 3302 ( $\nu$  O–H), 1463 ( $\delta_{as}$  CH<sub>3</sub>), 1379 ( $\delta_s$  CH<sub>3</sub>).

#### 2.7. Disodium 2 $\beta$ ,3 $\alpha$ -dihydroxycholest-5-ene disulfate (**11**)

Trimethylamine-sulfur trioxide complex (52.6 mg, 0.38 mmol) was added to a solution of 2 $\beta$ ,3 $\alpha$ ,6 $\beta$ -trihydroxy-5 $\alpha$ -cholestane

(**10**) (7.8 mg, 0.019 mmol) in DMF (0.4 ml). The reaction mixture was irradiated and stirred at 150 °C for 7 min in a sealed tube in a microwave reactor and then quenched with water (1 ml). After evaporation to dryness the residue was eluted through Amberlite CG-120 (sodium form) with methanol, evaporated under reduced pressure and purified by solid phase extraction over silica gel (55  $\mu$ m). Fractions eluted with  $CH_2Cl_2/MeOH$  (85:15) afforded pure disodium 2 $\beta$ ,3 $\alpha$ -dihydroxycholest-5-ene disulfate (**11**) (4.4 mg, 38%), m.p. >250 °C (MeOH).  $^1H$  NMR  $\delta$  (DMSO-*d*<sub>6</sub>): 0.63 (s, 3H, H-18), 0.83 (d,  $J = 6.6$  Hz, 6H, H-26, H-27), 0.89 (d,  $J = 6.3$  Hz, 3H, Me-21), 1.05 (s, 3H, H-19), 4.32 (m, 1H, H-2 $\alpha$ ), 4.40 (m, 1H, H-3 $\beta$ ), 5.17 (m, 1H, H-6).  $^{13}C$  NMR  $\delta$  (DMSO-*d*<sub>6</sub>): 32.4 (C-1), 72.7 (C-2), 72.2 (C-3), 37.1 (C-4), 139.4 (C-5), 120.6 (C-6), 31.2 (C-7), 30.7 (C-8), 49.8 (C-9), 36.2 (C-10), 20.2 (C-11), 39.2 (C-12), 42.3 (C-13), 56.1 (C-14), 23.7 (C-15), 27.6 (C-16), 55.3 (C-17), 11.15 (C-18), 18.3 (C-19), 35.0 (C-20), 18.5 (C-21), 35.5 (C-22), 23.0 (C-23), 38.7 (C-24), 27.2 (C-25), 22.1 (C-26), 22.6 (C-27). HREIMS (ESI–), calculated for  $C_{27}H_{44}NaO_8S_2$  [ $M - Na$ ]<sup>–</sup>: 583.2381, found  $m/z = 599.2361$ .

#### 2.8. Disodium 2 $\beta$ ,3 $\alpha$ ,6 $\beta$ -trihydroxy-5 $\alpha$ -cholestan-2 $\beta$ ,3 $\alpha$ -disulfate (**12**)

Two portions of 7 mg of sodium borohydride were added to a solution of 8.6 mg (0.014 mmol) of disodium 2 $\beta$ ,3 $\alpha$ -dihydroxy-5 $\alpha$ -cholestan-6-one disulfate (**1**) in 0.40 ml of methanol at room temperature for 4 h. After acidification with 0.5 M HCl solution, methanol was added and the mixture was evaporated to eliminate the B(OMe)<sub>3</sub>. The reaction product was purified by solid phase extraction over silica gel (55  $\mu$ m). Fractions eluted with dichloromethane/methanol (85:15) afforded pure disodium 2 $\beta$ ,3 $\alpha$ ,6 $\beta$ -trihydroxy-5 $\alpha$ -cholestan-2 $\beta$ ,3 $\alpha$ -disulfate (**12**) (8.4 mg, 97%), m.p. >250 °C (decomp) (acetone–H<sub>2</sub>O).  $^1H$  NMR  $\delta$  (DMSO-*d*<sub>6</sub>): 0.64 (s, 3H, H-18), 0.83 (d,  $J = 6.6$  Hz, 3H, H-26), 0.84 (d,  $J = 6.6$  Hz, 3H, H-27), 0.89 (d,  $J = 6.6$  Hz, 3H, H-21), 1.03 (s, 3H, H-19), 3.53 (m, 1H, H-6 $\alpha$ ), 4.30 (m, 1H, H-2 $\alpha$ ), 4.37 (m, 1-H, H-3 $\beta$ ).  $^{13}C$  NMR (DMSO-*d*<sub>6</sub>): 39.0 (C-1), 73.2 (C-2), 73.4 (C-3), 27.0 (C-4), 41.5 (C-5), 69.7 (C-6), 39.9 (C-7), 29.7 (C-8), 54.8 (C-9), 35.1 (C-10), 20.3 (C-11), 39.6 (C-12), 42.2 (C-13), 55.9 (C-14), 23.9 (C-15), 27.8 (C-16), 55.7 (C-17), 11.9 (C-18), 17.2 (C-19), 35.2 (C-20), 18.6 (C-21), 35.7 (C-22), 23.2 (C-23), 38.8 (C-24), 27.4 (C-25), 22.7 (C-26), 22.4 (C-27). HREIMS (ESI–), calculated for  $C_{27}H_{46}NaO_9S_2$  [ $M - Na$ ]<sup>–</sup>: 601.2486, found  $m/z = 601.2486$ . ATR FT-IR (ZnSe,  $cm^{-1}$ ) 3317 ( $\nu$  O–H), 1462 ( $\delta_{as}$  CH<sub>3</sub>), 1373 ( $\delta_s$  CH<sub>3</sub>), 1212 ( $\delta_s$  S=O).

#### 2.9. Trisodium 2 $\beta$ ,3 $\alpha$ ,6 $\beta$ -trihydroxy-5 $\alpha$ -cholestane trisulfate (**13**)

Trimethylamine-sulfur trioxide complex (13.5 mg, 0.097 mmol) was added to a solution of disodium 2 $\beta$ ,3 $\alpha$ ,6 $\beta$ -trihydroxy-5 $\alpha$ -cholestan-2 $\beta$ ,3 $\alpha$ -disulfate (**12**) (12.5 mg, 0.020 mmol) in DMF (0.25 ml). The reaction mixture was irradiated and stirred at 60 °C for an hour in a sealed tube in a microwave reactor and then quenched with water (0.5 ml). After evaporation to dryness the residue was eluted through Amberlite CG-120 (sodium form) with methanol, evaporated under reduced pressure. Preparative HPLC (methanol/water (75:25 v/v)) of the crude product afforded pure trisodium 2 $\beta$ ,3 $\alpha$ ,6 $\beta$ -trihydroxy-5 $\alpha$ -cholestane trisulfate (**13**) (12.8 mg, 88%), m.p. >250 °C (decomp. at 85 °C).  $^1H$  NMR  $\delta$  (DMSO-*d*<sub>6</sub>): 0.65 (s, 3H, H-18), 0.84 (d,  $J = 6.6$  Hz, 6H, H-26, H-27), 0.89 (d,  $J = 6.4$  Hz, 3H, Me-21), 0.95 (s, 3H, H-19), 4.06 (m, 1H, H-6 $\alpha$ ), 4.30 (m, 1H, H-2 $\alpha$ ), 4.37 (m, 1H, H-3 $\beta$ ).  $^{13}C$  NMR  $\delta$  (DMSO-*d*<sub>6</sub>): 36.6 (C-1), 73.0 (C-2), 73.2 (C-3), 26.7 (C-4), 41.2 (C-5), 75.6 (C-6), 38.9 (C-7), 30.0 (C-8), 54.5 (C-9), 35.0 (C-10), 20.3 (C-11), 39.8 (C-12), 42.2 (C-13), 55.9 (C-14), 23.9 (C-15), 27.8 (C-16), 55.7 (C-17), 12.0 (C-18), 16.9 (C-19), 35.2 (C-20), 18.6 (C-21), 35.7 (C-22), 23.1 (C-23), 38.8 (C-24), 27.4 (C-25), 22.4 (C-26), 22.7 (C-27). HREIMS (ESI–), calculated for  $C_{27}H_{45}Na_3O_{12}S_3$

[M–Na]<sup>+</sup>: 703.1874, found *m/z* = 703.1894. ATR FT-IR (ZnSe, cm<sup>-1</sup>) 1463 ( $\delta_{\text{as}}$  CH<sub>3</sub>), 1382 ( $\delta_{\text{s}}$  CH<sub>3</sub>), 1203 ( $\delta_{\text{s}}$  S=O).

#### 2.10. 2 $\beta$ ,3 $\alpha$ -Dihydroxy-5 $\beta$ -cholestan-6-one (**14**)

To a solution of 2 $\beta$ ,3 $\alpha$ -dihydroxy-5 $\alpha$ -cholestan-6-one (**3**) (8.1 mg, 0.019 mmol) in 1.7 ml of ethanol under reflux, small pieces of Na were added until no 2 $\beta$ ,3 $\alpha$ -dihydroxy-5 $\alpha$ -cholestan-6-one was detected by TLC. Then, 10 ml of 15% NaCl solution was added and the steroid was extracted with EtOAc (3 × 10 ml). The combined organic extracts were dried over anhydrous MgSO<sub>4</sub> and evaporated to dryness. The reaction mixture was purified by solid phase extraction over silica gel (55  $\mu$ m) using cyclohexane/EtOAc (60:40) to give 6.6 mg (81.5%) of **14** as a white crystalline solid, m.p. 157–158 °C (acetone–H<sub>2</sub>O). <sup>1</sup>H NMR  $\delta$  (CDCl<sub>3</sub>): 0.65 (s, 3H, H-18), 0.86 (d, *J* = 6.7 Hz, 6H, H-26, H-27), 0.89 (s, 3H, H-19), 0.91 (d, *J* = 6.5 Hz, 3H, Me-21), 2.19 (m, 1-H, H-5 $\beta$ ), 3.43 (m, 1-H, H-3 $\beta$ ), 3.65 (ddd, *J* = 12.5 Hz, 8.7 Hz, 4.0 Hz 1H, H-2 $\alpha$ ). <sup>13</sup>C NMR  $\delta$  (CDCl<sub>3</sub>): 32.7 (C-1), 70.5 (C-2), 75.3 (C-3), 41.9 (C-4), 59.0 (C-5), 213.2 (C-6), 42.7 (C-7), 36.9 (C-8), 41.1 (C-9), 42.0 (C-10), 20.8 (C-11), 39.4 (C-12), 42.9 (C-13), 56.6 (C-14), 23.7 (C-15), 27.9 (C-16), 55.9 (C-17), 11.7 (C-18), 23.0 (C-19), 35.5 (C-20), 18.4 (C-21), 35.8 (C-22), 23.6 (C-23), 39.3 (C-24), 27.8 (C-25), 23.5 (C-26), 22.3 (C-27). Anal. calcd for C<sub>27</sub>H<sub>46</sub>O<sub>3</sub> · 1/4 H<sub>2</sub>O, C 76.64, H 11.07, O 12.29. Found, C 76.38, H 10.58. HREIMS (ESI<sup>+</sup>), calculated for C<sub>27</sub>H<sub>46</sub>NaO<sub>3</sub> [M + Na]<sup>+</sup>: 441.3339, found *m/z* = 441.3340. ATR FT-IR (ZnSe, cm<sup>-1</sup>) 3454, 3376 (ν O–H), 1690 (ν C=O), 1457 ( $\delta_{\text{as}}$  CH<sub>3</sub>), 1376 ( $\delta_{\text{s}}$  CH<sub>3</sub>).

#### 2.11. 5 $\alpha$ -Cholest-2-en-6 $\alpha$ -ol (**15**)

To a solution of 5 $\alpha$ -cholest-2-en-6-one (**5**) (79.9 mg, 0.21 mmol) in 16.5 ml of *n*-propanol under reflux, small pieces of Na were added until no cholest-2-en-6-one was detected by TLC. Then, 10 ml of 15% NaCl solution was added and the steroid was extracted with AcOEt (3 × 20 ml). The combined AcOEt extracts were dried over anhydrous MgSO<sub>4</sub> and evaporated to dryness. The reaction product was purified by dry column flash chromatography on silica gel using hexane/EtOAc (98:2) to give 72.3 mg (90%) of **15** as a white crystalline solid, m.p. 120–121 °C (acetone–H<sub>2</sub>O). <sup>1</sup>H NMR  $\delta$  (CDCl<sub>3</sub>): 0.66 (s, 3H, H-18), 0.76 (s, 3H, H-19), 0.86 (d, *J* = 6.6 Hz, 6H, H-26, H-27), 0.91 (d, *J* = 6.5 Hz, 3H, H-21), 3.44 (dt, *J* = 10.9 Hz, 4.6 Hz, H-6 $\beta$ ), 5.59 (m, 1H, H-2), 5.67 (m, 1H, H-3). <sup>13</sup>C NMR  $\delta$  (CDCl<sub>3</sub>): 40.1 (C-1), 125.7 (C-2), 125.3 (C-3), 25.9 (C-4), 48.8 (C-5), 71.8 (C-6), 41.5 (C-7), 34.4 (C-8), 53.7 (C-9), 35.6 (C-10), 21.0 (C-11), 40.0 (C-12), 42.7 (C-13), 53.4 (C-14), 24.3 (C-15), 28.3 (C-16), 56.3 (C-17), 12.1 (C-18), 13.2 (C-19), 35.9 (C-20), 18.8 (C-21), 36.3 (C-22), 24.0 (C-23), 39.7 (C-24), 28.2 (C-25), 22.7 (C-26), 23.0 (C-27). Anal. calcd for C<sub>27</sub>H<sub>46</sub>O, C 83.87, H 11.99, O 4.14. Found, C 83.50, H 12.27. HREIMS (ESI<sup>+</sup>), calculated for C<sub>27</sub>H<sub>46</sub>NaO [M + Na]<sup>+</sup>: 409.3441, found *m/z* = 409.3442. FT-IR (NaBr, film, cm<sup>-1</sup>) 3270 (ν O–H), 3017 (ν C=C–H), 1468 ( $\delta_{\text{as}}$  CH<sub>3</sub>), 1382 ( $\delta_{\text{s}}$  CH<sub>3</sub>).

#### 2.12. 2 $\alpha$ ,3 $\alpha$ -Epoxy-5 $\alpha$ -cholestan-6 $\alpha$ -ol (**16**)

A 10% Na<sub>2</sub>CO<sub>3</sub> solution (2.02 ml) was added to 5 $\alpha$ -cholest-2-ene-6 $\alpha$ -ol (**15**) (51.2 mg, 0.13 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (1.8 ml). The reaction mixture was stirred vigorously at 5 °C and *m*-chloroperbenzoic acid (74.3 mg, 0.43 mmol) in 0.8 ml of CH<sub>2</sub>Cl<sub>2</sub> was added slowly. The mixture was stirred for 4 h at room temperature, and then the aqueous layer was extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 10 ml). The combined CH<sub>2</sub>Cl<sub>2</sub> extracts were washed successively with 5% Na<sub>2</sub>SO<sub>3</sub> solution, saturated NaHCO<sub>3</sub> solution and water, dried over anhydrous MgSO<sub>4</sub> and evaporated to dryness. The reaction product was purified by solid phase extraction over silica gel (55  $\mu$ m). Fractions


eluted with cyclohexane/EtOAc (90:10) afforded pure 2 $\alpha$ ,3 $\alpha$ -epoxy-5 $\alpha$ -cholestan-6 $\alpha$ -ol (**16**) (37.2 mg, 71%), as a colorless syrup. <sup>1</sup>H NMR  $\delta$  (CDCl<sub>3</sub>): 0.64 (s, 3H, H-18), 0.77 (s, 3H, H-19), 0.86 (d, *J* = 6.6 Hz, 3H, H-26), 0.86 (d, *J* = 6.7 Hz, 3H, H-27), 0.90 (d, *J* = 6.6 Hz, 3H, Me-21), 3.12 (dd, *J* = 6.0 Hz, 4.0 Hz, 1H H-2 $\beta$ ), 3.24 (m, 1H, H-3 $\beta$ ), 3.38 (dt, *J* = 11.1 Hz, 4.7 Hz, H-6 $\beta$ ). <sup>13</sup>C NMR  $\delta$  (CDCl<sub>3</sub>): 38.7 (C-1), 50.7 (C-2), 52.4 (C-3), 24.6 (C-4), 44.1 (C-5), 71.1 (C-6), 41.8 (C-7), 34.2 (C-8), 53.4 (C-9), 34.6 (C-10), 20.9 (C-11), 39.8 (C-12), 42.5 (C-13), 56.1 (C-14), 24.3 (C-15), 28.3 (C-16), 56.3 (C-17), 12.0 (C-18), 14.5 (C-19), 35.9 (C-20), 18.8 (C-21), 36.3 (C-22), 23.9 (C-23), 39.6 (C-24), 28.2 (C-25), 22.7 (C-26), 23.0 (C-27). HREIMS (ESI<sup>+</sup>), calculated for C<sub>27</sub>H<sub>46</sub>NaO<sub>2</sub> [M + Na]<sup>+</sup>: 425.3390, found *m/z* = 425.3396. FT-IR (NaBr, film, cm<sup>-1</sup>) 3406 (ν O–H), 1469 ( $\delta_{\text{as}}$  CH<sub>3</sub>), 1377 ( $\delta_{\text{s}}$  CH<sub>3</sub>), 1255 (ν<sub>s</sub> C–O–C), 808 (ν<sub>as</sub> C–O–C).

#### 2.13. 2 $\beta$ ,3 $\alpha$ ,6 $\alpha$ -Trihydroxy-5 $\alpha$ -cholestane (**17**)

A solution of epoxide **16** (34.8 mg, 0.086 mmol) in THF (1.77 ml) was treated with 1 N H<sub>2</sub>SO<sub>4</sub> (0.05 ml) and stirred for 24 h at room temperature. After neutralization with saturated NaHCO<sub>3</sub> solution the mixture was evaporated to fifth initial volume, diluted with water (5 ml), and extracted with EtOAc (3 × 5 ml). The combined organic extracts were washed with water, dried over anhydrous MgSO<sub>4</sub>, filtered and evaporated to dryness. The reaction product was purified by solid phase extraction over silica gel (55  $\mu$ m). Fractions eluted with cyclohexane/EtOAc (40:60) afforded pure 2 $\beta$ ,3 $\alpha$ ,6 $\alpha$ -trihydroxy-5 $\alpha$ -cholestane (**17**). (35.6 mg, 98%), m.p. 249–250 °C (acetone–H<sub>2</sub>O). <sup>1</sup>H NMR  $\delta$  (CDCl<sub>3</sub>/CD<sub>3</sub>OD; 4:1): 0.66 (s, 3H, H-18), 0.87 (d, *J* = 6.6 Hz, 6H, H-26, H-27), 0.98 (s, 3H, H-19), 0.91 (d, *J* = 6.5 Hz, 3H, Me-21), 3.81 (m, 1H, H-2 $\alpha$ ), 3.38 (dt, *J* = 11.0 Hz, 4.5 Hz, H-6 $\beta$ ), 3.84 (m, 1H, H-3 $\beta$ ). <sup>13</sup>C NMR  $\delta$  (CDCl<sub>3</sub>/CD<sub>3</sub>OD; 4:1): 40.4 (C-1), 70.5 (C-2), 69.9 (C-3), 25.4 (C-4), 45.9 (C-5), 69.3 (C-6), 41.7 (C-7), 34.0 (C-8), 54.9 (C-9), 36.7 (C-10), 24.0 (C-11), 40.1 (C-12), 42.8 (C-13), 56.5 (C-14)\*, 24.3 (C-15), 28.4 (C-16), 56.5 (C-17)\*, 12.2 (C-18), 15.2 (C-19), 36.0 (C-20), 18.8 (C-21), 36.4 (C-22), 21.0 (C-23), 39.7 (C-24), 28.2 (C-25), 22.6 (C-26), 22.9 (C-27). (\*) Signals might be interchangeable. Anal. calcd for C<sub>27</sub>H<sub>48</sub>O<sub>3</sub>, C 77.09, H 11.50, O 11.41. Found, C 77.34, H 11.95. HREIMS (ESI<sup>+</sup>), calculated for C<sub>27</sub>H<sub>48</sub>NaO<sub>3</sub> [M + Na]<sup>+</sup>: 443.3496, found *m/z* = 443.3494. FT-IR (NaBr, film, cm<sup>-1</sup>) 3262 (ν O–H), 1460 ( $\delta_{\text{as}}$  CH<sub>3</sub>), 1377 ( $\delta_{\text{s}}$  CH<sub>3</sub>).

#### 2.14. Trisodium 2 $\beta$ ,3 $\alpha$ ,6 $\alpha$ -trihydroxy-5 $\alpha$ -cholestane trisulfate (**18**)

Trimethylamine-sulfur trioxide complex (23.8 mg, 0.17 mmol) was added to a solution of 2 $\beta$ ,3 $\alpha$ ,6 $\alpha$ -trihydroxy-5 $\alpha$ -cholestane (**17**) (7.2 mg, 0.017 mmol) in DMF (0.61 ml). The reaction mixture was irradiated and stirred at 150 °C for 9 min in a sealed tube in a microwave reactor and then quenched with water (0.5 ml). After evaporation to dryness the residue was eluted through Amberlite CG-120 (sodium form) with methanol, evaporated under reduced pressure and purified by solid phase extraction over silica gel (55  $\mu$ m). Fractions eluted with CH<sub>2</sub>Cl<sub>2</sub>/MeOH (85:15) afforded pure trisodium 2 $\beta$ ,3 $\alpha$ ,6 $\alpha$ -trihydroxy-5 $\alpha$ -cholestane trisulfate (**18**) (9.4 mg, 76%), m.p. 189–192 °C (decomp.). <sup>1</sup>H NMR  $\delta$  (DMSO-*d*<sub>6</sub>): 0.62 (s, 3H, H-18), 0.84 (d, *J* = 6.6 Hz, 6H, H-26, H-27), 0.87 (s, 3H, H-19), 0.88 (d, *J* = 6.6 Hz, 3H, Me-21), 3.82 (dt, *J* = 10.9 Hz, 4.3 Hz, H-6 $\beta$ ), 4.37 (m, 1H, H-3 $\beta$ ), 4.45 (m, 1H, H-2 $\alpha$ ). <sup>13</sup>C NMR  $\delta$  (DMSO-*d*<sub>6</sub>): 37.5 (C-1), 72.4 (C-2), 72.3 (C-3), 23.7 (C-4), 43.8 (C-5), 74.0 (C-6), 38.9 (C-7), 33.4 (C-8), 54.1 (C-9), 35.9 (C-10), 20.4 (C-11), 39.5 (C-12), 42.2 (C-13), 55.9 (C-14), 23.8 (C-15), 27.8 (C-16), 55.6 (C-17), 11.9 (C-18), 14.7 (C-19), 35.2 (C-20), 18.5 (C-21), 35.6 (C-22), 23.1 (C-23), 38.9 (C-24), 27.4 (C-25), 22.4 (C-26), 22.7 (C-27). HREIMS (ESI<sup>-</sup>), calculated for C<sub>27</sub>H<sub>45</sub>Na<sub>2</sub>O<sub>12</sub>S<sub>3</sub>



**Fig. 2.** Chemical structures of compounds **6** and **8** and their sulfated analogs (**7**, **9**).

[M–Na]<sup>–</sup>: 703.1874, found *m/z* = 703.1865. ATR FT-IR (cm<sup>–1</sup>) 1485(δ<sub>as</sub> CH<sub>3</sub>), 1380 (δ<sub>s</sub> CH<sub>3</sub>), 1210 (δ<sub>s</sub> S=O).

### 2.15. Cholinesterase inhibition assays

Electric eel (*Torpedo californica*) AChE and horse serum BChE were used as source of both cholinesterases. AChE and BChE inhibiting activities were measured *in vitro* by the spectrophotometric method developed by Ellman with slight modification [13]. The lyophilized enzyme, 500U AChE/300U BChE, was prepared in buffer phosphate A (8 mM K<sub>2</sub>HPO<sub>4</sub>, 2.3 mM NaH<sub>2</sub>PO<sub>4</sub>) to obtain 5/3 U/mL stock solution. Further enzyme dilution was carried out with buffer phosphate B (8 mM K<sub>2</sub>HPO<sub>4</sub>, 2.3 mM NaH<sub>2</sub>PO<sub>4</sub>, 0.15 M NaCl, 0.05% Tween 20, pH 7.6) to produce 0.126/0.06 U/mL enzyme solution. Samples were dissolved in buffer B. Compounds **6** and **8** required 2.5% of MeOH as cosolvent. Enzyme solution (300 μL) and 300 μL of sample solution were mixed in a test tube and incubated for 60/120 min at room temperature. The reaction was started by adding 600 μL of the substrate solution (0.5 mM DTNB, 0.6 mM ATCl/BTCl, 0.1 M Na<sub>2</sub>HPO<sub>4</sub>, pH 7.5). The absorbance was read at 405 nm for 180 s at 27 °C. Enzyme activity was calculated by comparing reaction rates for the sample to the blank. All the reactions were performed in triplicate. IC<sub>50</sub> values were deter-


mined with GraphPad Prism 5. Eserine (99%) was used as the reference AChE/BChE inhibitor.

## 3. Results and discussion


### 3.1. Chemistry

#### 3.1.1. Synthesis of disodium (2α,3α)- and (2β,3β)-dihydroxy-5α-cholestan-6-one disulfate


Isomeric disulfated steroids **7** and **9** (Fig. 2) were synthesized according to the following sequence. First, intermediate **5** was obtained from cholesterol in four steps as described previously [11]. Osmium-catalyzed asymmetric dihydroxylation [12] of double bond of **5** using K<sub>3</sub>Fe(CN)<sub>6</sub> as cooxidant and hydroquinine-1,4-phthalazinediyl diether [(DHQ)<sub>2</sub>-PHAL] as chiral ligand gave, after purification, 65% yield of the 2β,3β diol (**6**) and 35% of the 2α,3α diastereomer (**8**). When hydroquinidine-1,4-phthalazinediyl diether [(DHQD)<sub>2</sub>-PHAL] was used as the chiral ligand, the 2α,3α diastereomer (**8**) was obtained in 51% yield together with **6** (28%) and starting material **5** (12%), which was recycled. These results are in accordance with reported synthesis of *cis*-diols using these hydroxylation reagents [14,15]. Subsequent treatment of diols **6** and **8** with 8 equiv. of trimethylamine-sulfur trioxide complex for 7 min at 150 °C at a microwave reactor [11] afforded the corresponding ammonium sulfates, which were transformed via ion exchange into the disodium salts **7** and **9**. The structures of **7** and **9** were confirmed by analysis of the proton and carbon NMR chemical shifts at C-2 and C-3. Resonances showing H-2α at 4.84 ppm (m) and H-3α at 4.31 ppm (dt, *J* = 12.1, 3.7 Hz) for compound **7** and H-2β at 4.44 ppm (ddd, *J* = 12.3, 4.7, 3 Hz) and H-3β at 4.86 ppm (m) for isomer **9** were characteristic of the presence of two sulfate groups at C-2 and C-3 in *cis* position. This was in accordance with the chemical shifts observed for C-2 (76.47 ppm (isomer **7**) and 75.44 ppm (isomer **9**)) and C-3 (78.30 ppm (isomer **7**) and 76.40 ppm (isomer **9**)) in the <sup>13</sup>C NMR spectra, as determined from the HSQC and HMBC spectra [16].



**Scheme 1.** Conditions: (a) NaBH<sub>4</sub>, methanol, room temperature (b) 20 equiv. Me<sub>3</sub>N.SO<sub>3</sub>, DMF, 7 min, 150 °C, microwave (c) Amberlite CG-120 (MeOH) (d) 8 equiv. Me<sub>3</sub>N.SO<sub>3</sub>, DMF, 7 min, 150 °C, microwave (e) NaBH<sub>4</sub>, methanol, room temperature (f) 5 equiv. Me<sub>3</sub>N.SO<sub>3</sub>, DMF, 1 h, 60 °C, microwave.



**Scheme 2.** Conditions: (a) Sodium, ethanol, reflux (b) 8 equiv. Me<sub>3</sub>N.SO<sub>3</sub>, DMF, 7 min, 150 °C, microwave (c) Amberlite CG-120 (MeOH).



**Scheme 3.** Conditions: (a) Sodium, *n*-propanol, reflux (b) *m*-CIPBA, Na<sub>2</sub>CO<sub>3</sub>, H<sub>2</sub>O-Cl<sub>2</sub>CH<sub>2</sub>, room temperature, 4 h (c) H<sub>2</sub>SO<sub>4</sub>, THF room temperature, 24 h (d) 15 equiv. Me<sub>3</sub>N·SO<sub>3</sub>, DMF, 150 °C, microwave (e) Amberlite CG-120 (MeOH).

**Table 1**

Summary of the in vitro antiacetylcholinesterase activities.

Compound	IC <sub>50</sub> (μM)
1	14.59 ± 0.88
3	59.65 ± 2.30
6	>200
7	40.94 ± 8.62
8	>200
9	30.66 ± 6.91
10	>200
11	>200
12	>200
13	>200
17	>200
18	15.48 ± 0.88
Eserine	0.0113 ± 0.0011

### 3.1.2. Synthesis of trisodium (2β,3α,6β)-trihydroxy-5α-cholestane trisulfate

The strategy followed to obtain compound **13** is shown in Scheme 1. The diol **3** was prepared from cholesterol in 6 steps as described previously [11]. Reduction of the carbonyl group with NaBH<sub>4</sub>/MeOH from the α less hindered face of the steroid gave the 2β,3α,6β-triol (**10**) in 87% yield. The β configuration of the hydroxyl group at C-6 was inferred from NOE interactions between signals at 1.62 ppm (H-5α) and 3.71 (H-6α) ppm. Further sulfation of **10** with 20 equiv. of trimethylamine-sulfur trioxide complex for 7 min at 150 °C at a microwave reactor and elution through Amberlite CG-120 (sodium form) afforded a mixture of products, as observed by TLC. Purification of the mixture gave disulfated steroid **11** in 34% yield. The <sup>1</sup>H NMR spectrum of **11** showed a multiplet at 5.17 ppm (H-5) and two olefinic carbons at 139.4 (C-5) and 120.6 ppm (C-6), characteristic of a Δ<sup>5</sup> steroid [17]. This was confirmed by correlation of the C-19 methyl signal at 18.40 ppm with the multiplet at 5.17 ppm in the HMBC spectrum. In order to avoid the elimination of the axial hydroxyl group at C-6, we developed a new strategy based on sulfation of the diol **3** [11], reduction of the carbonyl group, and further sulfation of the hydroxyl at C-6 in milder conditions (Scheme 1). In this way, reduction of the disulfated ketone **1** with NaBH<sub>4</sub>/MeOH, sulfation of the C-6 (β) hydroxyl of **12** with 5 equiv. of trimethylamine-sulfur trioxide complex for 1 h at 60 °C at a microwave reactor and transformation via ion exchange into the sodium salts afforded trisulfated triol **13** in 89% yield from **1**. The <sup>1</sup>H NMR spectrum of **13** showed a broad singlet at 4.06 ppm for H-6β, as confirmed by NOESY correlations.

### 3.1.3. Synthesis of trisodium (2β,3α,6α)-trihydroxy-5α-cholestane trisulfate

Reduction of **3** with sodium in ethanol under reflux gave the epimer at C-5 (**14**) instead of the expected 2β,3α,6α-triol (Scheme 2). The <sup>13</sup>C NMR spectrum of **14** showed a C-19 methyl signal at 23.0 ppm indicative of a *cis* conformation for rings A and B [17]. This was confirmed by NOESY correlations of the signal of H-5β at 2.19 ppm with CH<sub>3</sub>-19 and H-3β. Evidently, epimerization at C-5 via enolate formation was favored over reduction of the carbonyl group due to the pseudo-equatorial position of both hydroxyl groups in **14**. On the other hand, sulfation of **14** in the same conditions as for **3** gave the disulfated steroid **1** in 84.1% yield.

Looking forward to prepare the 2β,3α,6α-triol **17** we followed the strategy of Murphy et al. [18] for the synthesis of trisulfated analog **18** of sokotrasterol sulfate, a natural product isolated from the sponge *Topsentia ophirhaphidites* (Scheme 3). Reduction of the ketone **5** with sodium in *n*-propanol (reflux) gave 5α-cholest-2-en-6α-ol (**15**). Further epoxidation and acid-catalyzed epoxide ring opening of **16** gave triol **17**. The <sup>1</sup>H NMR spectrum of **17** showed two multiplets at δ 3.81 (H-2α) and 3.84 (H-3β) ppm, geminal to hydroxyl groups at C-2 (70.47 ppm) and C-3 (69.93 ppm) and a double triplet at 3.38 ppm (H-6β) (*J* = 11.0 Hz, 4.5 Hz), as determined by analysis of <sup>13</sup>C NMR, HSQC, HMBC and NOESY spectra. Sulfation of **17** with 15 equiv. of trimethylamine-sulfur trioxide complex for 9 min at 150° in microwave reactor and transformation via ion exchange afforded trisodium 2β,3α,6α-trihydroxy-5α-cholestane trisulfate (**18**) in 76% yield (Scheme 3).

### 3.1.4. Evaluation of the acetylcholinesterase inhibitory activity

The acetylcholinesterase inhibitory activity of compounds **6–13**, **17** and **18** was evaluated and compared to that of analogs **1** and **3** (Table 1) previously synthesized by our group [10–11]. The compounds were found to be less active than the reference compound eserine. From the data shown in Table 1, *cis* disulfated compounds **7** and **9** were less active than isomer **1**, suggesting the importance of the sulfate configurations at C-2 and C-3 on the inhibitory activity. As reported previously [11], steroid **1** binds reversibly to the enzyme-substrate complex, yielding an inactive complex. This affinity is favored by hydrogen bonding interactions, which involve both sulfates at ring A. Presumably, a change in sulfate configurations at C-2 and C-3, as in isomers **7** and **9**, decreases their affinity to the enzyme-substrate complex. Interestingly, 2β,3α,6α-trisulfated steroid **18** was the most active compound with an IC<sub>50</sub> value of 15.48 μM comparable to that of compound **1** (14.59 μM). On the other hand, compound **13** with a sulfate group at C-6 (β) showed no inhibitory activity (IC<sub>50</sub> > 200 μM) as well as

**Table 2**  
Summary of the in vitro anticholinesterase activities.

Compound	IC <sub>50</sub> (μM)	Ratio IC <sub>50</sub> BChE/AChE
1	>200	>13.7
18	176.10 ± 1.29	11.4
Eserine	0.0143 ± 0.0013	1.27

disulfated analogs **11** and **12** and alcohols **6**, **8**, **10** and **17**. These results indicate that the presence of *trans* diaxial sulfate groups at C-2 and C-3 together with a carbonyl or sulphate group at C-6 ( $\alpha$ ) increase the inhibitory activity.

In order to determine the AChE/BChE selectivity of the most active compounds **1** and **18**, their butyrylcholinesterase activity was evaluated. As shown in Table 2, the butyrylcholinesterase activity of **1** and **18** was one magnitude lower than that against AChE, revealing a selective inhibitor profile. This result is interesting because BChE has the ability of delaying the onset and decreasing the rate of A $\beta$  fibril formation in vitro, a central event in the pathogenesis of AD [19,20].

### Acknowledgments

We thank the University of Buenos Aires and the National Research Council of Argentina (CONICET) for financial support of this work. V.R. thanks CONICET for a Doctoral fellowship. A.P.M. and M.S.M. are Research Members of CONICET.

### References

- [1] Goedert M, Spillantini MG. A century of Alzheimer's Disease. *Science* 2006;314:777–81.
- [2] Parle M, Dhingra D, Kulkarni SK. Neuromodulators of learning and memory. *Asia Pac J Pharmacol* 2004;16:89–99.
- [3] Rosenberry TL. Acetylcholinesterase. *Adv Enzymol Relat Areas Mol Biol* 1975;43:103–218.
- [4] Dvir H, Silman I, Harel M, Rosenberry TL, Sussman JL. Acetylcholinesterase: from 3D structure to function. *Chem Biol Interact* 2010;187:10–22.
- [5] Peng D-Y, Sun Q, Zhu X-L, Lin H-Y, Chen Q, et al. Design, synthesis and bioevaluation of benzamides: novel AChE inhibitors with multi-functions on BChE, A $\beta$  aggregations and  $\beta$ -secretase. *Bioorg Med Chem* 2012;20:6739–50.
- [6] Enz A, Amstutz R, Boddeke H, Gmelin G, Malonowski J. Brain selective inhibition of AChE: a novel approach to therapy for Alzheimer's disease. *Prog Brain Res* 1993;98:431–5.
- [7] Langjae R, Bussarawit S, Yuenyongsawad S, Ingkaninan K, Plubrukarn A. Acetylcholinesterase-inhibiting steroidal alkaloid from the sponge *Corticium* sp. *Steroids* 2007;72:682–5.
- [8] Porcel J, Montalban X. Anticholinesterasics in the treatment of cognitive impairment in multiple sclerosis. *J Neurol Sci* 2006;245:177–81.
- [9] Vela Gurovic MS, Castro MJ, Richmond V, Faraoni MB, Maier MS, Murray AP. Triterpenoids with acetylcholinesterase inhibition from *Chuquiraga erinacea* D. Don. Subsp. *erinacea* (Asteraceae). *Planta Medica* 2010;76:607–10.
- [10] Garrido Santos GA, Murray AP, Pujol CA, Damonte EB, Maier MS. Synthesis and antiviral activity of sulfated and acetylated derivatives of 2 $\beta$ ,3 $\alpha$ -dihydroxy-5 $\alpha$ -cholestane. *Steroids* 2003;68:125–32.
- [11] Richmond V, Garrido Santos G, Murray AP, Maier MS. Synthesis and acetylcholinesterase inhibitory activity of 2 $\beta$ ,3 $\alpha$ -disulfoxy-5 $\alpha$ -cholestan-6-one. *Steroids* 2011;76:1160–5.
- [12] Becker H, Soler MA, Sharpless KB. Selective asymmetric dihydroxylation of polyenes. *Tetrahedron* 1995;51:1345–76.
- [13] Ellman GL, Courtney KD, Andres Jr V, Featherstone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. *Biochem Pharmacol* 1961;7:88–95.
- [14] Ramirez JA, Gros EG, Galagovsky LR. Effects on bioactivity due to C-5 heteroatom substituents on synthetic 28-homobrassinosteroid analogs. *Tetrahedron* 2000;56:6171–80.
- [15] Jeong KS, Sjö P, Sharpless KB. Asymmetric dihydroxylation of enynes. *Tetrahedron Lett* 1992;33:3833–6.
- [16] Makarieva TN, Shubina LK, Kalinovsky AI, Stonik VA, Elyakov GB. Steroids in Porifera. II. Steroid derivatives from two sponges of the family Halichondriidae. Sokotrasterol sulfate, a marine steroid with a new pattern of side chain alkylation. *Steroids* 1983;42:267–81.
- [17] Goad LJ, Akihisa T. Analysis of sterols. Blackie; 1997.
- [18] Murphy M, Larrivé B, Pollet I, Craig KS, Williams DE, et al. Identification of sokotrasterol sulfate as a novel proangiogenic steroid. *Circ Res* 2006;99:257–65.
- [19] Podoly E, Bruck T, Diamant S, Melamed-Book N, Weiss A, et al. Human recombinant butyrylcholinesterase purified from the milk of transgenic goats interacts with beta-amyloid fibrils and suppresses their formation in vitro. *Neurodegener Dis* 2008;5:232–6.
- [20] Diamant S, Podoly E, Friedler A, Ligumsky H, Livnah O, et al. Butyrylcholinesterase attenuates amyloid fibril formation in vitro. *Proc Natl Acad Sci* 2006;103:8628–33.